

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

“LACOSAMIDE INJECTION” OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Lacosamide Injection (20ml:0.2g)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Lacosamide selectively enhances the slow inactivation of sodium channels. The prolonged inactivation of sodium channels reduces the inward flow of sodium ions and lowers the excitability of neurons more effectively. When oral administration is not feasible, lacosamide injection offers an alternative medication option for patients and is used as adjunctive therapy for partial-onset seizures in patients with epilepsy aged 4 years and older. As an antiepileptic drug, lacosamide has few side effects, does not undergo hepatic metabolism and has no clinically significant interactions with other antiepileptic drugs. Owing to its unique mechanism of action, lacosamide provides a novel treatment option for partial-onset seizures in patients with epilepsy. The Group has obtained the registration approvals for Lacosamide Tablets (100mg and 50mg) in May and August 2021 respectively.

The approval of the Product will further enrich the Group’s product portfolio for nervous system diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 11 July 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. WU Guizhen as independent non-executive directors.

** For identification purposes only*